GROUP MEMBERS:

Angellano, Marinelle Faye

Agrave, Aedan Paul
Cariaga, Desiree
Gutierrez, Darilyn Grace S.
MERCK AND CO.
 Merck & Co.
Merck & Co. began in 1668 in Darmstadt, Germany.
Friedrich Jacob Merck opened the pharmaceutical
company under the name Angel Pharmacy (Engel-
Apotheke).
The company became a manufacturer in 1827. Heinrich
Emanuel Merck changed the course of the business under
its new name E. Merck.
 Merck & Co.

1891, the company’s U.S. branch Merck & Co. opened.

George Merck, Heinrich’s grandson, headed its
operation.
 Merck & Co.

manufactures a variety of well-known pharmaceutical

drugs, vaccines and animal-health products.
It made the first smallpox vaccine for commercial use in
the U.S
It is also the maker of the painkiller Vioxx and the HPV
vaccine Gardasil.
For more than 130 years, Merck has been driven by the
view that great medicines and vaccines can change the
world.
Merck is one of the largest pharmaceutical companies in
the world. In 2021, it raked in over $48 billion in
revenues.
Merck has more than 50 pharmaceutical products to its
name.
 History of Merck & co.
January 1, 1891 - Merck & co. was founded in the U.S.
1898 - Merck & Co. sold the first commercially used
smallpox vaccine in the U.S.
1899 - The first Merck Manual published
1925 - George W. Merck became president of merck &
co. company
1933 - Merck Research Laboratory created
- founded in Rahway, New Jersey.
1936 - Vitamin B1 synthesized and published the results
in the Journal of the American Chemical Society.
1940s - Funded the discovery of and distributed
breakthrough antibiotic streptomycin
- Dr. Selman Waksman and Albert Schatz
1948 - Merck entered the animal health market with
sulfaquinoxaline
1950 - Cortisone first commercially synthesized Dr.
Lewis Sarett, a researcher at Merck Research
Laboratory in Rahway
1953 - Merck merged with Sharp & Dohme
1957 - The Merck Foundation was created
1958 - DIURIL launched to treat high blood pressure
1970s - Treatment for trichinosis for animals discovered
1963, Merck manufactured the first measles vaccine. It
made the first mumps vaccine in 1967.
 1971 - Merck began distributing the M-M-R vaccine-
developed by Drs. Maurice Hilleman and Eugene B.
Buynak.
- M-M-R was composed of three vaccines:
ATTENUVAX, an updated version of Merck's measles
vaccine; MERUVAX, a rubella vaccine; and MUMPSVAX,
Merck's mumps vaccine.
1977 - First pneumonia vaccine was approved
1987 - Merck introduced the first commercial statin
1996 - CRIXIVAN (INDINAVIR SULFATE) approved
by the FDA
1998 - SINGULAIR approved by FDA
2009 - Merck and Schering-Plough merged
2014 - BRAVECTO approved by the FDA for the
Merck Animal Health division
2019 - ERVEBO® approved by the FDA
Popular Merck Pharmaceuticals
Clarinex - Antihistamine
Fosamax - Slows bone loss
Implanon - Upper arm birth
control implant
Januvia and Janumet - Type 2
diabetes drugs (DPP-4 inhibitors)
Keytruda - Injectable cancer
medication
NuvaRing - Vaginal contraceptive
ring
Propecia - Hair-loss prevention drug
Proventil - Albuterol inhaler
Singulair - Asthma medication
Zocor - Cholesterol medicine
(statin)
Popular Merck Vaccines
Gardasil - HPV vaccine
MMR - Measles-mumps-rubella
vaccine
Pneumovax - Pneumococcal
vaccine
Recombivax HB - Hepatitis B
vaccine
RotaTeq - Rotavirus vaccine
Varivax - Chickenpox (varicella)
vaccine
Zostavax - Shingles (herpes zoster)
vaccine
BioNTech SE
a biotechnology company, develops and commercializes
immunotherapies for cancer and other infectious diseases
Incorporated in 2008
Mainz, Germany
BioNTech is founded by Prof. Ugur Sahin, M.D., Prof. Özlem Türeci,
M.D., and Prof. Christoph Huber, M.D., to develop and produce
treatments for individualized cancer immunotherapy.
Revenue: 17.3 billion euros (2017-2022)
Employees: 4,500 full-time employees (2022)
Competitors: Merck & Co., Moderna, GlaxoSmithKline & Sanofi
Early 2020
PARTNERSHIP
August 16, 2018
 HISTORY
Developed the first non-nucleoside modified RNA vaccines for
personalized cancer therapy in 2012.
Pioneered intravenous nanoparticle delivery of mRNA vaccines in
humans in 2015.
Improved mRNA potency by 1,000-fold, inducing a comprehensive
immune response.
Created a nanoparticle-based delivery strategy for body-wide targeting
of antigen-presenting cells via intravenous administration.
Advanced individualized mRNA-based cancer immunotherapy into
clinical trials.
2006 - Improvements to the non-coding regions increasing the stability and
translational efficiency of RNA molecules in dendritic cells
2008 - Engineering RNA to route the encoded cargo to specific places within
the cell which increases the CD8 and CD4 response significantly
2009 - BioNTech acquires EUFETS and JPT Peptide Technologies
2012 - Start of the first Phase 1 clinical trial with RNA immunotherapy in
melanoma, today known as our FixVac approach.
2014 - Start of the first Phase 1 clinical trial with a fully individualized RNA
immunotherapy in melanoma, today known as the iNeST approach
2014-2018 - Strategic collaborations across the pipeline (Bayer
Animal Health, Genentech, a member of the Roche Group,
Genmab, Siemens, Sanofi, Regeneron, Genevant, Pfizer,
University of Pennsylvania).
2015 - RNA cancer immunotherapy data published in Nature.
2019 - BioNTech becomes a publicly traded company on the
NASDAQ Global Select Market under the ticker symbol BNTX
2020 - Acquisition of Neon Therapeutics to bolster our global
leadership position in T cell therapies and open US headquarters
2020 - Establishment of BioNTech Manufacturing Marburg to produce COVID-
19 vaccine, which became one of the largest mRNA manufacturing facilities in
2021
2020 - Establishment of BioNTech Manufacturing Marburg to produce COVID-
19 vaccine, which became one of the largest mRNA manufacturing facilities in
2021
2021 - BioNTech acquires PhagoMed BioPharma GmbH, an Austrian
biotechnology company specialized in the development of a new class of
antibacterials
2021 - The first colorectal cancer patient was treated with the individualized
mRNA cancer vaccine candidate BNT122 in a Phase 2 clinical trial
2022 - Introduction of first modular mRNA
manufacturing facility to promote scalable
vaccine production in Africa, called
BioNTainer. Groundbreaking for BioNTech’s
first mRNA vaccine manufacturing facility in
Africa.

2022 - Phase 1 clinical trial for malaria vaccine

program BNT165 initiated
 MISSION
We are committed to improving the health of people
worldwide with our fundamental research and
development of immunotherapies. We believe in
scientific rigor, innovation and passion as driving force.
 VISION

Our vision is to harness the power of the

immune system to develop novel therapies
against cancer & infectious diseases.
REFERENCES:

BioNTech. (n.d.). https://www.biontech.com/int/en/home.html